Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PLUR)

Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions

GlobeNewswire October 18, 2018

U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

GlobeNewswire October 16, 2018

Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study

GlobeNewswire October 10, 2018

Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update

GlobeNewswire September 27, 2018

Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation

GlobeNewswire September 25, 2018

Pluristem Initiates Two Pivotal Phase III Studies in Israel

GlobeNewswire August 8, 2018

Pluristem Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure

GlobeNewswire July 26, 2018

Pluristem Signs Collaboration Agreement With Thermo Fisher Scientific

GlobeNewswire July 9, 2018

Pluristem and Fukushima University Report Positive Data: PLX-R18 Increases Survival Rates and Mitigates Severe Intestinal Damage after Acute Radiation Exposure

GlobeNewswire June 25, 2018

U.S. Department of Defense to Study Pluristem’s PLX-R18 for the Treatment of Mustard Gas Injuries

GlobeNewswire June 19, 2018

Pluristem to Open Weekly Market Trading at TASE Following Positive Study Results

GlobeNewswire June 14, 2018

Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study

GlobeNewswire June 12, 2018

Pluristem to Announce Top-Line Results of Its Multinational Phase II Intermittent Claudication Study on June 12, 2018

GlobeNewswire June 4, 2018

The Stem Cell Market is Projected to Grow Due to Technological Advancements

PR Newswire May 31, 2018

Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

GlobeNewswire May 10, 2018

FDA Clears New Drug Application For Pluristem's PLX-R18; What's Next?

Benzinga.com April 30, 2018

36 Stocks Moving In Monday's Mid-Day Session

Benzinga.com April 30, 2018

U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation

GlobeNewswire April 30, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com April 25, 2018

$7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells

GlobeNewswire October 2, 2017